Abstract 522P
Background
Oxaliplatin based hepatic arterial infusions (HAI) combined with systemic and/or targeted therapy are a very promising treatment strategy for colorectal cancer with liver-only metastasis. However, it has not been fully explored in the setting of liver metastasis secondary to other types of tumors. The available data on this subject consists of case reports and mini-case series. We conducted this descriptive analysis to study the efficacy and safety of HAIC to treat liver metastasis in non-colorectal cancers.
Methods
Between 1986 and 2023, single-center consecutive patients presenting with liver metastasis secondary to non-colorectal cancer, who received at least one cycle of HAIC, were analyzed.
Results
A total of 82 patients were included. 51% were women and 49% were men. 85% had unresectable or potentially resectable hepatic disease upon diagnosis. The median number of HAIC cycles received was 4. The median number of previous chemotherapy lines was 1. Tumor histologic origin was as follows: 15% biliary, 12% breast, anus 11%, oeso-gastric 9.8%, lung 7.3%, pancreas 7.3%, liver primitive 6.1%, neuroendocrine 6.1%, and other 26%. Patients were subsequently divided into two groups : the first including patients whose tumor is of gastro-intestinal origin (n=51), and the second including all other non gastro-intestinal localisations (n=31). Median hepatic progression free survival was 11 months, identical between the two groups. The best responses observed during HAIC are presented in the table. The most frequent grade 3/4 toxicities were neutropenia (22%), peripheral sensory neuropathy (10%), and decreased platelet count (10.2%). The treatment resulted in curative intent surgery in 11% of the patients. Table: 522P
| Characteristic | Overall(N=82) | GI(N=51) | Non-GI(N=31) | p-value |
| Best response (RECIST) | 0.54 | |||
| Complete | 26(32%) | 15(29%) | 11(35.5%) | |
| Partial | 17(21%) | 11(22%) | 6(19.5%) | |
| Stable disease | 24(29%) | 17(33%) | 7(22.5%) | |
| Progressive disease | 11(13%) | 5(10%) | 6(19.5%) | |
| NC | 4(5%) | 3(6%) | 1(3%) |
Conclusions
HAIC administration as a part of the therapeutic strategy of liver-metastasis in non-colorectal cancer is feasible and efficient, as it shows an ORR of 53% and a disease control rate of 83%, without additional toxicities. Thus, it could potentially provide an interesting additional therapeutic line.
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.